Mycrodose Therapeutics Expands Scientific Advisory Board with the Addition of Dr. Yavorsky and Dr. Jacques

San Diego, California–(Newsfile Corp. – December 14, 2021) – Mycrodose Therapeutics (“Mycrodose“), a leading US pharmaceutical company developing advanced drug delivery technologies for use with psychedelic compounds, is pleased to announce the appointment of Dr. Christian Yavorsky and Dr. Jacqueline Jacques to its Scientific Advisory Board.

Dr. Yavorsky is a psychologist by training and has worked in clinical trials in the pharmaceutical industry for nearly twenty years. He has worked primarily in Phase II and III clinical trials in psychiatry and neurology including depression, bipolar disorder, schizophrenia and anxiety as well as Tourette’s, Fragile X, Alzheimer’s, Parkinson’s and a range of Rare and Orphan indications.

Dr. Yavorsky worked on the esketamine trial for Janssen, the Pharmaceutical Companies of Johnson & Johnson, and has since pioneered measurement technologies in the psychedelic space. He is currently the co-chair of the Rapid-acting Antidepressant working group at ISCTM and has been involved in over 60 Phase I-IV clinical trials. Dr. Yavorsky joined Mycrodose to augment manufacturing and preclinical trial research and provide direction on appropriate targets for the Company’s delivery technology.

“The addition of Dr. Yavorsky has been instrumental in providing guidance to our Executive Team’s decision to expand specific partnerships with other pharmaceutical companies using our proprietary advanced drug delivery (ADD) technologies,” said Chad Conner, CEO of Mycrodose Therapeutics, “We are thrilled to have such an experienced psychologist with extensive experience navigating complex clinical trials at Mycrodose as we expands more products into pre-clinical and clinical FDA trials.”

Dr. Yavorsky added, “I am proud to be part of the Mycrodose Therapeutics team pioneering novel methods of delivery and the application of a range of psychedelic compounds in psychiatry, neurology and rare and orphan indications.”

Dr. Jacques is a Naturopathic Doctor and Fellow of the Obesity Society with over twenty years of expertise in medical nutrition. She is currently the Chief Medical Officer of CB2 therapeutics, a joint venture between Thorne HealthTech and Tetra Bio-Pharma. Dr Jacques has spent much of her career in the dietary supplement industry as a formulator, speaker, writer, and executive, including being a co-founder of Bariatric Advantage. She has also served on the boards/advisory boards for the Obesity Action Coalition, the Samueli Integrative Health Institute, Alkemist Labs, YOR Health, Bodywise International, and the California Naturopathic Doctors Association.

“The addition of Dr. Jacques gives our advisory team a huge advantage going forward,” said Chad Conner, CEO of Mycrodose Therapeutics. “Jacqueline’s experience with and expertise of how botanical and pharmaceutical compounds interact with the human body is world-renowned. We are very fortunate to have her as part of our expanding company.”

“It’s an honor to be able to serve as an advisor to Mycrodose Therapeutics. Their advanced delivery technology holds the potential to greatly expand the target audience for emerging therapies such as psilocybin. I’m especially excited about their focus on mental health, addiction, and obesity – conditions that I am particularly passionate about and are still ineffectively treated in millions,” said Dr. Jacques.

The goal of Mycrodose Therapeutics’ Scientific and Research Advisory Board is in part to focus on compelling scientific discoveries and overcoming challenges involved in the safe and effective delivery of psychedelic compounds.

​​

About Mycrodose Therapeutics

Mycrodose Therapeutics is a US-Based pharmaceutical company headquartered in San Diego, California specializing in the development of advanced drug delivery (ADD) systems utilizing psychedelic compounds to treat mental health and cognitive degenerative diseases. Mycrodose is one of only a few private companies that has been granted a Schedule I License and been approved by the United States Drug Enforcement Agency (DEA), State of California Attorney General’s Research Advisory Board, and The US Food & Drug Administration (FDA) to research four (4) psychedelic compounds: psilocybin, LSD, MDMA, and DMT. The company believes that its IP-Protected Sustained Microdosing Technology™ is a smarter and safer approach to delivering pharmaceutical compounds to patients of all ages and that this technology allows for these compounds to be utilized for a wider range of indications and applications.

For more information about Mycrodose Therapeutics, please contact:

Patrick Eckstrom
Chief Operating Officer
Mycrodose Therapeutics
Email: Patrick@MycrodoseThera.com
Phone: 1-619-494-1367
Website: www.MycrodoseThera.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/107496